taurine has been researched along with Shock, Septic in 5 studies
Shock, Septic: Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.
Excerpt | Relevance | Reference |
---|---|---|
"Glycine has been well characterized in spinal cord as an inhibitory neurotransmitter which activates a glycine-gated chloride channel (GlyR) expressed in postsynaptic membranes." | 2.40 | Glycine: a new anti-inflammatory immunonutrient. ( Bradford, B; Enomoto, N; Ikejema, K; Rose, ML; Rusyn, I; Schemmer, P; Seabra, V; Stacklewitz, RF; Thurman, RG; Wheeler, MD; Yin, M; Zhong, Z, 1999) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (40.00) | 18.7374 |
1990's | 2 (40.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Vermeulen, MA | 1 |
van Stijn, MF | 1 |
Visser, M | 1 |
Lemmens, SM | 1 |
Houdijk, AP | 1 |
van Leeuwen, PA | 1 |
Oudemans-van Straaten, HM | 1 |
Janssen, HF | 1 |
Lombardini, JB | 1 |
Lust, RM | 1 |
Wang, WY | 1 |
Wheeler, MD | 1 |
Ikejema, K | 1 |
Enomoto, N | 1 |
Stacklewitz, RF | 1 |
Seabra, V | 1 |
Zhong, Z | 1 |
Yin, M | 1 |
Schemmer, P | 1 |
Rose, ML | 1 |
Rusyn, I | 1 |
Bradford, B | 1 |
Thurman, RG | 1 |
McCartney, AC | 1 |
Browne, MK | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Evaluation of the Capability of a Glycine Oral Supplement for Diminishing Bronchial Inflammation in Children With Cystic Fibrosis[NCT01417481] | Phase 2 | 13 participants (Actual) | Interventional | 2012-03-31 | Terminated (stopped due to Some of the researchers finished their participation in the study.) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
Intervention | log (percent change) (Mean) |
---|---|
Glycine | -0.3908 |
Placebo | 0.2035 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
Intervention | log (percent change) (Mean) |
---|---|
Glycine | -0.0819 |
Placebo | 0.1668 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
Intervention | log (percent change) (Mean) |
---|---|
Glycine | -0.00007 |
Placebo | 0.1739 |
"To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).~Each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms." (NCT01417481)
Timeframe: 8 weeks
Intervention | Percentage of baseline (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Cough questionnaire score | Appetite questionnaire score | Energy questionnaire score | Body weight | Height | Heart rate | Respiratory rate | Temperature | |
Glycine | 81.1 | 89.1 | 84.6 | 101.6 | 100.5 | 103.5 | 94.8 | 100.0 |
Placebo | 89.1 | 132.1 | 111.5 | 103.6 | 100.5 | 98.1 | 109.0 | 100.1 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
Intervention | Percentage of baseline (Mean) | ||
---|---|---|---|
Forced expiratory volume at first second (FEV1) | Forced expiratory flow at 25%FVC (FEF25) | Maximal forced expiratory flow (FEFmax, PEFR) | |
Glycine | 109.7 | 133.9 | 115.3 |
Placebo | 91.4 | 83.3 | 91.2 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
Intervention | Percentage of baseline (Mean) | |
---|---|---|
Forced vital capacity (FVC) | Forced expiratory flow at 75%FVC (FEF75) | |
Glycine | 104.1 | 111.8 |
Placebo | 100.6 | 108.9 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
Intervention | Percentage of baseline (Mean) | ||
---|---|---|---|
Peripheral oxygen saturation (SpO2) | FEV1/FVC | Forced expiratory flow at 50%FVC (FEF50) | |
Glycine | 105.2 | 105.2 | 115.5 |
Placebo | 98.9 | 94.9 | 93.1 |
"To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).~In the symptoms questionnaire, each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms." (NCT01417481)
Timeframe: 8 weeks
Intervention | Percentage of baseline (Mean) | ||
---|---|---|---|
Sputum questionnaire score | Dyspnea questionnaire score | Total questionnaire score | |
Glycine | 82.0 | 75.6 | 77.7 |
Placebo | 102.6 | 103.8 | 98.7 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
Intervention | log (percent change) (Mean) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Myeloperoxidase | IL-1 | IL-4 | IL-6 | IL-7 | IL-8 | IL-12 | IL-13 | G-CSF | IFN-gamma | MCP-1 | MIP-1beta | |
Glycine | -0.4361 | -0.1635 | 0.2964 | 0.0085 | 0.0356 | -0.1466 | 0.3203 | -0.0561 | -0.0776 | 0.3272 | -0.0836 | 0.0330 |
Placebo | -0.2906 | -0.0352 | 0.1470 | 0.2255 | 0.0819 | -0.2364 | 0.2603 | 0.1953 | 0.2272 | 0.3639 | 0.0472 | -0.0608 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
Intervention | log (percent change) (Mean) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Myeloperoxidase | IL-1 | IL-2 | IL-4 | IL-5 | IL-7 | IL-8 | IL-10 | IL-12 | IL-13 | IL-17 | IFN-gamma | MCP-1 | MIP-1beta | TNF-alpha | GM-CSF | |
Glycine | 0.1294 | -0.0918 | 0.0233 | -0.0161 | 0.2498 | 0.0611 | -0.0824 | 0.0549 | 0.1675 | 0.1630 | 0.0680 | 0.0248 | 0.0042 | -0.0303 | 0.0412 | -0.0538 |
Placebo | 0.0669 | -0.0102 | -0.0274 | 0.0522 | 0.1304 | 0.1387 | 0.0542 | 0.0074 | 0.0677 | 0.0953 | 0.1140 | 0.0649 | 0.2608 | 0.0977 | 0.1568 | -0.0822 |
1 review available for taurine and Shock, Septic
Article | Year |
---|---|
Glycine: a new anti-inflammatory immunonutrient.
Topics: Alcohols; Animals; Anti-Inflammatory Agents; Calcium Channels, L-Type; Chloride Channels; Cyclospori | 1999 |
1 trial available for taurine and Shock, Septic
Article | Year |
---|---|
Clinical studies on administration of taurolin in severe sepsis: a preliminary study.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Clinical Trials as Topic; Endotoxins; Female; Hum | 1988 |
3 other studies available for taurine and Shock, Septic
Article | Year |
---|---|
Taurine Concentrations Decrease in Critically Ill Patients With Shock Given Enteral Nutrition.
Topics: Amino Acids; APACHE; Critical Illness; Enteral Nutrition; Female; Hospital Mortality; Humans; Intens | 2016 |
Cardiac taurine levels during endotoxemia.
Topics: Animals; Blood Pressure; Cardiac Output; Dogs; Myocardium; Shock, Septic; Taurine | 1983 |
[Intestinal endotoxin translocation in endotoxemic rats].
Topics: Animals; Endothelins; Endotoxins; Intestinal Mucosa; Mice; Rats; Shock, Septic; Taurine; Toxemia | 1995 |